Literature DB >> 15167279

Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction.

Masao Sakabe1, Akira Fujiki, Kunihiro Nishida, Masataka Sugao, Hidehiko Nagasawa, Takayuki Tsuneda, Koichi Mizumaki, Hiroshi Inoue.   

Abstract

UNLABELLED: Effects of enalapril on a canine model of atrial pacing-induced atrial fibrillation (AF) with rapid ventricular responses were determined.
METHODS: Four weeks of atrial rapid pacing was performed on twenty-four beagles pretreated with placebo (Group I, n = 14) or enalapril 1 mg/kg (Group II, n = 10). Atrial effective refractory period (ERP), P-wave width, duration of AF, and left ventricular ejection fraction (LVEF) were evaluated every week. AF cycle length was determined by spectral analyses of fibrillation waves. Quantitative analysis of histology was added.
RESULTS: After 4 weeks of pacing, P-wave width was longer in Group I than in Group II, and the duration of induced AF was significantly longer in Group I (59.6 +/- 66.3 seconds) than in Group II (3.6 +/- 3.4 seconds, P < 0.05). AF cycle length was longer in Group I than in Group II despite similar shortening of atrial ERP. Mean ventricular rate during rapid atrial pacing was not different between the two groups. LVEF similarly decreased in both groups. Interstitial fibrosis and expression of connexin43 was greater in Group I than in Group II (interstitial fibrosis, 9.2 +/- 8.4 versus 1.9 +/- 2.1%, P < 0.05; connexin43, 5.3 +/- 2.2 versus 1.1 +/- 1.1%, P < 0.05).
CONCLUSIONS: Enalapril suppressed atrial pacing-induced AF with tachycardia-mediated cardiomyopathy by suppressing interstitial fibrosis, connexin43 over-expression and conduction delay.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167279     DOI: 10.1097/00005344-200406000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  21 in total

Review 1.  The Stress-Response MAP Kinase Signaling in Cardiac Arrhythmias.

Authors:  Xun Ai; Jiajie Yan; Elena Carrillo; Wenmao Ding
Journal:  Rev Physiol Biochem Pharmacol       Date:  2016       Impact factor: 5.545

Review 2.  Atrial Septal Defect and Atrial Fibrillation: The Known and Unknown.

Authors:  George E Blake; Dhanunjaya Lakkireddy
Journal:  J Atr Fibrillation       Date:  2008-09-16

3.  Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53.

Authors:  Naoya Kataoka; Kunihiro Nishida; Koshi Kinoshita; Tamotsu Sakamoto; Yosuke Nakatani; Yasushi Tsujino; Koichi Mizumaki; Hiroshi Inoue; Koichiro Kinugawa
Journal:  Heart Vessels       Date:  2016-05-28       Impact factor: 2.037

4.  Effects of metoprolol therapy on cardiac gap junction remodelling and conduction in human chronic atrial fibrillation.

Authors:  S Dhein; S Rothe; A Busch; D M Rojas Gomez; A Boldt; A Reutemann; T Seidel; A Salameh; B Pfannmüller; A Rastan; M Kostelka; F W Mohr
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 5.  Atrial fibrosis and the mechanisms of atrial fibrillation.

Authors:  Thomas H Everett; Jeffrey E Olgin
Journal:  Heart Rhythm       Date:  2006-12-28       Impact factor: 6.343

Review 6.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419

7.  A new role for extracellular Ca2+ in gap-junction remodeling: studies in humans and rats.

Authors:  S Dhein; N Duerrschmidt; A Scholl; A Boldt; J S Schulte; B Pfannmüller; D Rojas-Gomez; A Scheffler; J-A Haefliger; N Doll; F-W Mohr
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-02-16       Impact factor: 3.000

8.  On the different roles of AT1 and AT2 receptors in stretch-induced changes of connexin43 expression and localisation.

Authors:  Aida Salameh; Daniel Apel; Jorge Gonzalez Casanova; Sandy von Salisch; Friedrich-Wilhelm Mohr; Ingo Daehnert; Stefan Dhein
Journal:  Pflugers Arch       Date:  2012-09-25       Impact factor: 3.657

Review 9.  The Role Of Renin Angiotensin System In Atrial Fibrillation.

Authors:  Girish M Nair; Pablo B Nery; Calum J Redpath; David H Birnie
Journal:  J Atr Fibrillation       Date:  2014-04-30

Review 10.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.